TRT, GLP-1s, ED.See the real costbefore you subscribe.

Both platelet-rich plasma (PRP) injections and low-intensity shockwave therapy (Li-ESWT) produce statistically measurable improvements in erectile function scores—but neither has cleared the bar required for guideline-endorsed treatment, and neither is FDA-approved for erectile…

For men with hypogonadism who want to father children, the choice between conventional testosterone replacement and enclomiphene is not a matter of preference — it is a matter of biology.

Topical dutasteride produces greater improvements in hair density than topical finasteride in head-to-head trials, but finasteride has the larger evidence base, more predictable systemic exposure data, and — as of September 2026 — a cleaner regulatory track record for compounded…

Retatrutide produces greater peak weight loss than tirzepatide in clinical data — roughly 24.2% body weight reduction at 48 weeks versus tirzepatide's 22.5% at 72 weeks — but calling it "better" depends entirely on what a researcher or clinician means by that word.

PT-141 (bremelanotide) is the only peptide with phase 3 randomized trial data and FDA approval in the sexual desire space — everything else researchers compare it against is operating on preclinical evidence or early human data at best.

For men with confirmed low testosterone, the core clinical question in 2026 is no longer simply whether to treat — it's which axis to target. Exogenous testosterone replacement restores circulating levels directly but suppresses the body's own production machinery; enclomiphene…

Adults taking semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound) should target 1.2–1.6 grams of protein per kilogram of reference body weight per day — roughly double the standard dietary recommendation — to preserve lean mass during pharmacologically induced weight loss.

PP405, a first-in-class topical mitochondrial pyruvate carrier inhibitor, produces faster visible regrowth than minoxidil in early trials — but minoxidil has decades of controlled-trial data behind it, and PP405 is not yet commercially available.

Both versions of Wegovy — the once-weekly subcutaneous injection and the once-daily oral tablet — produce clinically meaningful weight loss using the same active drug, semaglutide.